Expert Review of Neurotherapeutics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 6, 2025
Frontotemporal
dementia
(FTD)
encompasses
a
group
of
heterogeneous
neurodegenerative
disorders.
Aside
from
genetic
cases,
its
diagnosis
is
challenging,
particularly
in
the
early
stages
when
symptoms
are
ambiguous,
and
structural
neuroimaging
does
not
reveal
characteristic
patterns.
The
authors
performed
comprehensive
literature
search
through
MEDLINE,
Scopus,
Web
Science
databases
to
gather
evidence
aid
diagnostic
process
for
suspected
FTD
patients,
phases,
even
sporadic
ranging
established
promising
tools.
Blood-based
biomarkers
might
help
identify
very
neuropathological
guide
further
evaluations.
Subsequently,
neurophysiological
measures
reflecting
functional
changes
cortical
excitatory/inhibitory
circuits,
along
with
assessing
brain
network,
connectivity,
metabolism,
perfusion
alterations,
could
detect
specific
associated
decades
before
symptom
onset.
As
advances,
cognitive-behavioral
profiles
atrophy
patterns
emerge,
distinguishing
subtypes.
Emerging
disease-modifying
therapies
require
patient
enrollment.
Therefore,
paradigm
shift
needed
-
relying
on
typical
cognitive
advanced
cases
widely
applicable
biomarkers,
primarily
fluid
and,
subsequently,
where
appropriate.
Additionally,
exploring
subjective
complaints
behavioral
detected
by
home-based
technologies
be
crucial
diagnosis.
Discover Mental Health,
Journal Year:
2024,
Volume and Issue:
4(1)
Published: Jan. 4, 2024
Abstract
Depression
is
a
common
and
devastating
neuropsychiatric
symptom
in
the
elderly
patients
with
dementia.
In
particular,
nearly
80%
of
Alzheimer’s
Disease
dementia
experience
depression
during
disease
development
progression.
However,
it
unknown
whether
shares
same
molecular
mechanisms
as
presenting
primary
psychiatric
or
occurs
persists
through
alternative
mechanisms.
this
review,
we
discuss
how
clinical
presentation
treatment
differ
between
disease,
focus
on
major
depressive
disorder.
Then,
hypothesize
several
that
may
be
unique
to
such
neuropathological
changes,
inflammation,
vascular
events.
Finally,
existing
issues
future
directions
for
investigation
Chinese Medicine,
Journal Year:
2024,
Volume and Issue:
19(1)
Published: Feb. 28, 2024
Abstract
Alzheimer’s
disease
(AD)
is
a
neurodegenerative
with
insidious
onset
and
progressive
development.
It
clinically
characterized
by
cognitive
impairment,
memory
impairment
behavioral
change.
Chinese
herbal
medicine
acupuncture
are
important
components
of
traditional
(TCM),
commonly
used
in
clinical
treatment
AD.
This
paper
systematically
summarizes
the
research
progress
natural
products
AD,
which
combined
existing
preclinical
evidence,
based
on
comprehensive
review
neuroinflammation,
discusses
efficacy
potential
mechanisms
Resveratrol,
curcumin,
kaempferol
other
can
significantly
inhibit
neuroinflammation
AD
vivo
vitro,
candidates
for
Acupuncture
alleviate
improving
synaptic
plasticity,
nerve
cell
apoptosis
reducing
production
aggregation
amyloid
β
protein
(Aβ)
brain.
has
characteristics
early,
safe,
effective
benign
bidirectional
adjustment.
The
purpose
this
to
provide
basis
strategies
TCM
Graphical
Expert Review of Neurotherapeutics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 6, 2025
Frontotemporal
dementia
(FTD)
encompasses
a
group
of
heterogeneous
neurodegenerative
disorders.
Aside
from
genetic
cases,
its
diagnosis
is
challenging,
particularly
in
the
early
stages
when
symptoms
are
ambiguous,
and
structural
neuroimaging
does
not
reveal
characteristic
patterns.
The
authors
performed
comprehensive
literature
search
through
MEDLINE,
Scopus,
Web
Science
databases
to
gather
evidence
aid
diagnostic
process
for
suspected
FTD
patients,
phases,
even
sporadic
ranging
established
promising
tools.
Blood-based
biomarkers
might
help
identify
very
neuropathological
guide
further
evaluations.
Subsequently,
neurophysiological
measures
reflecting
functional
changes
cortical
excitatory/inhibitory
circuits,
along
with
assessing
brain
network,
connectivity,
metabolism,
perfusion
alterations,
could
detect
specific
associated
decades
before
symptom
onset.
As
advances,
cognitive-behavioral
profiles
atrophy
patterns
emerge,
distinguishing
subtypes.
Emerging
disease-modifying
therapies
require
patient
enrollment.
Therefore,
paradigm
shift
needed
-
relying
on
typical
cognitive
advanced
cases
widely
applicable
biomarkers,
primarily
fluid
and,
subsequently,
where
appropriate.
Additionally,
exploring
subjective
complaints
behavioral
detected
by
home-based
technologies
be
crucial
diagnosis.
